

**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings of claims in the application:

**Listing of Claims:**

1. (Currently Amended) A method of identifying an agent that binds to CCX-CKR2 on a cell, the method comprising,  
contacting a plurality of agents and a CCX-CKR2 ligand to a CCX-CKR2 polypeptide comprising an extracellular domain at least 95% identical to an extracellular domain of SEQ ID NO:2, or a SDF1 or I-TAC-binding fragment thereof, wherein the CCX-CKR2 ligand is SDF1 or I-TAC; and  
selecting an agent that competes with I-TAC or SDF1 for binding to the CCX-CKR2 polypeptide or fragment thereof, thereby identifying an agent that binds to CCX-CKR2 on a cell.
2. (Original) The method of claim 1, wherein the cell is a cancer cell.
3. (Original) The method of claim 1, further comprising testing the selected agent for the ability to bind to, or inhibit growth of, a cell.
4. (Original) The method of claim 3, wherein the cell is a cancer cell.
5. (Original) The method of claim 1, further comprising testing the selected agent for the ability to alter kidney function.
6. (Original) ~~The method of claim 1, further comprising testing the selected agent for the ability to alter brain or neuronal function.~~
5. (Original) The method of claim 1, further comprising testing the selected agent for the ability to change cell adhesion to endothelial cells.

6/8. (Original) The method of claim 1, wherein the agent is less than 1,500 daltons.

7/9. (Original) The method of claim 1, wherein the agent is an antibody.

8/10. (Original) The method of claim 1, wherein the CCX-CKR2 polypeptide comprises the sequence displayed in SEQ ID NO:2.

11-27. (Canceled)

16/28. (Currently amended) A method comprising contacting a cell with an agent that specifically binds to SEQ ID NO:2, wherein the agent competes with SDF-1 or ~~and~~ I-TAC for binding to a CCX-CKR2 polypeptide, and wherein the cell expresses a CCX-CKR2 polypeptide, comprising an extracellular domain at least 95% identical to an extracellular domain of SEQ ID NO:2.

11/29. (Original) The method of claim 28, wherein the agent is less than 1,500 daltons.

12/30. (Original) The method of claim 28, wherein the agent is an antibody.

13/31. (Original) The method of claim 28, wherein the CCX-CKR2 polypeptide is as displayed in SEQ ID NO:2.

14/32. (Original) The method of claim 28, wherein the agent is identified by a method comprising

contacting a plurality of agents to a CCX-CKR2 polypeptide comprising an extracellular domain at least 95% identical to an extracellular domain of SEQ ID NO:2, or a SDF1 or I-TAC-binding fragment thereof; and

selecting an agent that competes with I-TAC or SDF-1 for binding to the CCX-CKR2 polypeptide or fragment thereof, thereby identifying an agent that binds to a cancer cell.

33-38. (Canceled)

Appl. No. 10/698,541

Amdt. dated October 23, 2006

Reply to Office Action of June 22, 2006

PATENT

<sup>9</sup> 39. (New) The method of claim 2, wherein the CCX-CKR2 ligand is detectably-labeled and the selecting step comprises measuring the amount of labeled CCX-CKR2 ligand bound to the polypeptide in the presence of at least one of the plurality of agents.